Lung cancer: alternative rearrangements--targeting ROS1 in NSCLC.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

5 citing papers in PubMed, 7 citations in OpenAlex.

1. [Molecule pathology in the treatment of lung cancer-Interdisciplinary view of the importance in thoracic surgery].Der Chirurg; Zeitschrift fur alle Gebiete der operativen Medizen · 2022
   Review
2. Potential Molecular Signatures Predictive of Lung Cancer Brain Metastasis.Frontiers in oncology · 2018
   Review
3. Elucidation of Resistance Mechanisms to Second-Generation ALK Inhibitors Alectinib and Ceritinib in Non-Small Cell Lung Cancer Cells.Neoplasia (New York, N.Y.) · 2016
   Article
4. Large-scale RNA-Seq Transcriptome Analysis of 4043 Cancers and 548 Normal Tissue Controls across 12 TCGA Cancer Types.Scientific reports · 2015
   Article
5. C-arm cone-beam CT-guided transthoracic lung core needle biopsy as a standard diagnostic tool: an observational study.Medicine · 2015
   Observational

Corrections and comments

• Comment on
  Crizotinib in ROS1-rearranged non-small-cell lung cancer.2014

Authors and funding

1 author.

Funding

No grant is acknowledged in the PubMed record.

Abstract

PubMed holds no abstract for this paper.

Indexed as